Stocks Health care FBLG
NASDAQ · Health careFibroBiologics, Inc. (FBLG)
It posted a net loss of $18.1M. In fiscal 2025 capital spending exceeded operating cash flow by $16.7M. At June 30, 2026 it held $3.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 31, 2026.
Key facts about FibroBiologics, Inc.
- Net worth
- FibroBiologics, Inc. has a market value (market cap) of $6.3M at the latest share price, and shareholders' equity of $4.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $16.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on July 31, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- FibroBiologics, Inc.'s next report was expected around October 19, 2026 and is not on file with the SEC yet.
What FibroBiologics, Inc. does
FibroBiologics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker FBLG.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$18.6M | -$0.42 | -$16.7M |
| 2024 | n/a | -$11.2M | -$0.34 | -$12.1M |
| 2023 | n/a | -$16.5M | -$0.68 | -$6.9M |
| 2023 | n/a | -$5.1M | -$0.18 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What FibroBiologics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 18, 2026
- September 17, 2026Activist stake (5% or more) SCHEDULE 13D
- September 15, 2026
- September 9, 2026Additional proxy material DEFA14A
- August 24, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- July 31, 2026
- July 31, 2026Proxy statement DEF 14A
- July 24, 2026
- July 17, 2026Preliminary proxy statement PRE 14A
Insider trades
What the people running FibroBiologics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 15, 2026 | Khoja HamidChief Scientific Officer | Received as pay | 298,508 | $500K |
| March 4, 2026 | Khoja HamidChief Scientific Officer | Bought | 30,000 | $11.4K |
| March 4, 2026 | O'Heeron PeteCHIEF EXECUTIVE OFFICER, Director | Bought | 15,872 | $6K |
| March 3, 2026 | O'Heeron PeteCHIEF EXECUTIVE OFFICER, Director | Bought | 18,200 | $7.4K |
| March 2, 2026 | O'Heeron PeteCHIEF EXECUTIVE OFFICER, Director | Bought | 17,428 | $6.2K |
| March 2, 2026 | Davis JasonChief Financial Officer | Bought | 70,000 | $29K |
| February 27, 2026 | Garcia Ruben AGeneral Counsel | Bought | 40,000 | $13.1K |
| December 11, 2025 | Garcia Ruben AGeneral Counsel | Bought | 140,000 | $47.6K |
Who owns FBLG
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Pete O'Heeron13G, passive | 18.2% | February 12, 2025 |
| Armistice Capital, LLC13G, passive with 1 related filers | 9.99% | August 14, 2026 |
| Hamid Khoja13D, may seek influence | 7.5% | September 17, 2026 |
| Mike Newlin13G, passive | 5.58% | June 6, 2025 |
Largest institutional holders
Insiders
4 insiders reported holding 6,509,718 shares in total, about $6.1M at the last price.
| Holder | Shares |
|---|---|
| O'Heeron PeteCHIEF EXECUTIVE OFFICER, Director | 5,958,147 |
| Khoja HamidChief Scientific Officer | 301,571 |
| Garcia Ruben AGeneral Counsel | 180,000 |
| Davis JasonChief Financial Officer | 70,000 |
Questions about FBLG
What does FibroBiologics, Inc. do?
FibroBiologics, Inc. is a company in the Health care sector, listed on NASDAQ as FBLG. Its shares trade on NASDAQ under the ticker FBLG.
What is FibroBiologics, Inc.'s net worth?
FibroBiologics, Inc. has a market value (market cap) of $6.3M at the latest share price, and shareholders' equity of $4.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is FibroBiologics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $18.1M.
When did FibroBiologics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 31, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the shareholder vote results from September 18, 2026.
When is FibroBiologics, Inc.'s next earnings report?
FibroBiologics, Inc.'s next report was expected around October 19, 2026 and is not on file with the SEC yet.
Similar companies
Compare FBLG with
Follow FBLG
Get an email when FibroBiologics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values FibroBiologics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.